Pliant Therapeutics (PLRX) Cash from Investing Activities (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Cash from Investing Activities data on file, last reported at -$4.1 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$4.1 million, down 105.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.1 million (down 59.26% YoY), and the FY2025 annual result was $134.3 million, down 4.31% from the prior year.
• Cash from Investing Activities retreated to -$4.1 million in Q1 2026 per PLRX's latest filing, from $1.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $69.1 million in Q1 2025 and troughed at -$178.3 million in Q3 2022.
• A 5-year average of -$393294.1 and a median of $20.0 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities slumped 11478.71% in 2023, then soared 231.59% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $20.0 million in 2022, then surged by 59.43% to $31.9 million in 2023, then climbed by 22.59% to $39.1 million in 2024, then sank by 95.48% to $1.8 million in 2025, then slumped by 331.9% to -$4.1 million in 2026.
• Business Quant data shows PLRX's Cash from Investing Activities at -$4.1 million in Q1 2026, $1.8 million in Q4 2025, and $27.9 million in Q3 2025.